Ondansetron Kabi

Ondansetron, the active ingredient in Ondansetron Kabi, is a serotonin 5‑HT3 receptor antagonist presented as an intravenous solution for intravenous use. It prevents and treats chemotherapy‑induced, radiotherapy‑induced, and postoperative nausea and vomiting in patients undergoing these therapies.

GNH USA supplies Ondansetron Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, ensuring quality compliance with EU standards and providing reliable global distribution and regulatory support.

Ondansetron is used to control nausea and vomiting by targeting the serotonergic pathway involved in the emetic response.

Chemotherapy‑induced nausea and vomiting: reduces the frequency and severity of acute and delayed nausea and vomiting caused by cytotoxic chemotherapy agents. Radiotherapy‑induced nausea and vomiting: prevents nausea and vomiting that can occur during or after radiation treatment, improving patient comfort. Postoperative nausea and vomiting: helps to prevent nausea and vomiting following surgical procedures, facilitating faster recovery and discharge.

Ondansetron may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache: mild to moderate pain often transient. - Constipation: reduced bowel movements, may require laxatives. - Dizziness: sensation of light‑headedness, usually short‑lived. - Fatigue: generalized tiredness without exertion. - Diarrhea: loose stools, typically self‑limiting. - Injection site pain: discomfort at the IV site.

Serious or Rare Side Effects: - QT interval prolongation: may lead to cardiac arrhythmias. - Severe allergic reaction: anaphylaxis with rash, swelling, or breathing difficulty. - Serotonin syndrome: rare but potentially life‑threatening condition with agitation, hyperthermia, and neuromuscular abnormalities. - Hepatic dysfunction: abnormal liver enzymes or jaundice. - Hypotension: sudden drop in blood pressure, especially with rapid infusion.

When using Ondansetron, clinicians should consider several safety measures to minimize risk.

Assess cardiac risk: monitor ECG in patients with known QT prolongation. Review electrolyte status: correct hypokalemia or hypomagnesemia before administration. Evaluate hepatic function: adjust use in severe liver impairment. Use caution in pregnancy: limited data, weigh benefits against potential risks. Monitor for allergic reactions: discontinue if severe hypersensitivity occurs. Store at ambient temperature: keep in original container, protect from moisture and light.

Ondansetron can interact with other medications, affecting its safety or efficacy.

Major Interactions (Avoid): - Apomorphine: may cause severe hypotension and loss of consciousness. - Other QT‑prolonging agents: increased risk of cardiac arrhythmias. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise ondansetron plasma levels.

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., codeine): altered metabolism may occur. - Anticholinergic drugs: heightened risk of constipation. - Anesthetic agents (e.g., propofol): potential potentiation of sedation.